Initiators of Semaglutide in General Practice in New South Wales, 2020–2023: A Retrospective Cohort Study
Year: 2026
Type: article
Study design: Observational Study
Abstract: AIM: We aimed to analyse trends and demographic and clinical profiles in initial prescriptions of semaglutide ("Ozempic") by general practitioners in New South Wales between 2020 and 2023. METHOD: This retrospective cohort study used electronic medical records from the New South Wales Health Lumos program, covering 680 general practices from January 2020 to November 2023. Individuals aged ≥18 years with a first general practice prescription for semaglutide ("initiators") were included. Counts and proportions of semaglutide initiators by year, sex, age, socioeconomic status, body mass index, and type 2 diabetes mellitus (T2DM) status were compared over time. RESULTS: . CONCLUSIONS: The use of semaglutide in Australia is expanding rapidly, particularly among individuals without T2DM. Patterns in general practice prescribing of semaglutide differ by sex, T2DM status, and socioeconomic factors, raising important questions about equitable access. These trends underscore the need for coordinated policy responses to support fair and sustainable use as demand continues to grow.
Source: Heart Lung and Circulation
Institutions: UNSW Sydney, Centre for Big Data Research in Health, New South Wales Department of Health, Government of New South Wales, Royal Prince Alfred Hospital, The George Institute for Global Health, Australian National University, The University of Queensland, The University of Sydney, The George Institute for Global Health, Imperial College London
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,260
Awards: G5332123236, G7749945813
OpenAlex ID: W7128429825